US FDA lifts partial clinical hold on DBV Technologies VITESSE phase 3 pivotal trial
By, Admin1 min read
Share
DBV Technologies, a clinical-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
